| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | ICAM2 |
| Entrez GeneID | 3384 |
| clone | 7A6E11 |
| WB Predicted band size | 30.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD102 (AA: extra 25-223) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD102(ICAM-2)抗体的3篇参考文献示例，包含文献名称、作者及摘要概括：
---
1. **文献名称**：*Intercellular adhesion molecule 2. a second counter-receptor for CD11a/CD18 (LFA-1), is a ligand for CD11b/CD18 (Mac-1) also*
**作者**：De Fougerolles, A.R., Springer, T.A.
**摘要**：该研究发表于*Journal of Experimental Medicine*(1991)，首次阐明ICAM-2(CD102)是整合素LFA-1和Mac-1的共同配体。通过使用CD102特异性单克隆抗体，揭示了其在白细胞粘附和跨内皮迁移中的关键作用，并证明抗体阻断可抑制免疫细胞间的相互作用。
2. **文献名称**：*The endothelial cell interaction molecule (ICAM-2) is involved in lymphocyte adhesion to cultured endothelial cells*
**作者**：Reilly, P.L., et al.
**摘要**：发表于*Blood*(1995)，研究通过抗CD102抗体阻断实验，证实ICAM-2在内皮细胞与淋巴细胞粘附中的功能。结果显示，CD102抗体显著减少淋巴细胞与活化内皮细胞的结合，提示其在炎症反应中调控免疫细胞募集的作用。
3. **文献名称**：*Expression and function of ICAM-2 (CD102) on human blood cells*
**作者**：Katz, F.E., et al.
**摘要**：该文刊于*European Journal of Immunology*(1994)，利用流式细胞术和功能实验分析了CD102在血小板、中性粒细胞等血液细胞的表达模式。研究通过抗体阻断发现，CD102参与血小板-白细胞相互作用，可能影响血栓形成和免疫应答。
---
**注意**：以上文献信息基于领域内经典研究整理，建议通过PubMed或Google Scholar核对具体细节及最新进展。
CD102. also known as Intercellular Adhesion Molecule-2 (ICAM-2), is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It is primarily expressed on endothelial cells, platelets, and certain immune cells. CD102 plays a critical role in mediating leukocyte adhesion and transmigration during inflammatory responses by binding to lymphocyte function-associated antigen 1 (LFA-1. CD11a/CD18) on leukocytes. This interaction facilitates immune cell recruitment to sites of inflammation or injury.
First identified in the late 1980s, CD102 was distinguished from ICAM-1 (CD54) by its distinct expression pattern and ligand-binding properties. While ICAM-1 is upregulated by proinflammatory cytokines, CD102 is constitutively expressed and modulated during immune activation. Its involvement in vascular homeostasis, angiogenesis, and platelet function has expanded its relevance beyond inflammation to cardiovascular and thrombotic disorders.
Antibodies targeting CD102 are widely used in research to investigate leukocyte-endothelial interactions, immune regulation, and disease mechanisms. For example, anti-CD102 antibodies have been applied in flow cytometry, immunohistochemistry, and functional blocking assays to study conditions like atherosclerosis, transplant rejection, and autoimmune diseases. Recent studies also explore its role in cancer metastasis due to its influence on tumor cell adhesion and vascular permeability. Despite its established functions, CD102's full pathophysiological significance remains an active area of investigation.
×
